1 |
ClinicalTrials.gov (NCT04685915) Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
|
2 |
FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 210259
|
3 |
2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
|
4 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
5 |
ClinicalTrials.gov (NCT04346199) Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.. U.S. National Institutes of Health.
|
6 |
AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
|
7 |
FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
|
8 |
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020 Jun 5;5(48):eabd0110. doi: 10.1126/sciimmunol.abd0110. Epub 2020 Jun 5.
|
9 |
Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro. Chem Biol Interact. 2021 Aug 25;345:109559. doi: 10.1016/j.cbi.2021.109559. Epub 2021 Jun 18.
|
10 |
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30.
|
11 |
FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.
|
12 |
PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury. Toxicol Appl Pharmacol. 2019 Oct 15;381:114729. doi: 10.1016/j.taap.2019.114729. Epub 2019 Aug 22.
|
|
|
|
|
|
|